Looking forward to seeing the nsclc late breaker data. My focus is on 1-49% pd1 category and looking to see increase in PFS and maybe slight improvement in ORR. 1-49% pd1 patients is the bulk of nsclc so very commercially relevant. Efti definitely the best performing io/io combo in this setting - but will the benefit be marginally significant to get big pharma onboard for a ph3 or will they be left to run it solo?
also good to see slide on insight-004 combo with merck germany reappear in latest presentation. i thought insigh-004 showed a promising enough signal to eventuate to a new trial but perhaps merck germany not interested.
Looking forward to seeing the nsclc late breaker data. My focus...
-
- There are more pages in this discussion • 1,631 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.015(3.57%) |
Mkt cap ! $619.6M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 44.0¢ | 41.5¢ | $1.416M | 3.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 38735 | 42.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 41215 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |